The Centers for Medicare & Medicaid Services’ yesterday issued guidance regarding the calculation of a plan’s Medical Loss Ratio, which represents the percent of premium revenue that goes toward claims and activities that improve health care quality. CMS regulations require Medicaid and CHIP managed care plans to use an MLR target of 85 percent in developing rates, and to exclude prescription drug rebates from the claims costs used to calculate an MLR. CMS said the guidance clarifies that a prescription drug rebate means any price concession or discount received by the managed care plan or by its pharmacy benefit manager, regardless of who pays the rebate or discount. CMS Administrator Seema Verma expressed concern that some managed care plans are not accurately reporting pharmacy benefit “spread pricing” when they calculate and report MLRs. Spread pricing occurs when health plans contract with PBMs to manage their prescription drug benefits, and PBMs keep a portion of the amount paid to them by the health plans for prescription drugs instead of passing the full payments on to pharmacies.  

Related News Articles

Headline
The Food and Drug Administration Feb. 3 released an early alert on a heart pump issue from certain Abiomed products. The agency said Abiomed found its Impella…
Headline
The Centers for Medicare & Medicaid Services Jan. 29 issued a final rule regarding states non-uniform or non-broad-based provider tax, as authorized under…
Headline
The House Jan. 22 voted 341-88 to pass a three-bill minibus for fiscal year 2026 that includes funding for key health programs and other bipartisan health…
Headline
Stephanie Calcasola, R.N., chief quality officer and vice president of quality and safety at Hartford HealthCare, unpacks the programs, technology and cultural…
Headline
Wendy Kim, DNP, R.N., vice president and chief nursing officer of Henry Ford Health in Michigan, shares how the system’s virtual nursing program is reducing…
Headline
The Food and Drug Administration has identified a recall by Cook Medical of Zenith Alpha 2 Thoracic Endovascular Graft proximal components after Cook Medical…